These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 31603967)

  • 1. Bimatoprost-induced iris hyperpigmentation: beauty in the darkened eye of the beholder.
    Lipp MB; Athalye L; Nami N
    Cutis; 2019 Aug; 104(2):E7-E9. PubMed ID: 31603967
    [No Abstract]   [Full Text] [Related]  

  • 2. Recovery of orbital fat pad prolapsus and deepening of the lid sulcus from topical bimatoprost therapy: 2 case reports and review of the literature.
    Aydin S; Işikligil I; Tekşen YA; Kir E
    Cutan Ocul Toxicol; 2010 Sep; 29(3):212-6. PubMed ID: 20670089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of LATISSE (bimatoprost 0.03 per cent topical solution) on the ocular surface.
    Bitton E; Courey C; Giancola P; Diaconu V; Wise J; Wittich W
    Clin Exp Optom; 2017 Nov; 100(6):583-589. PubMed ID: 28122407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low incidence of iris pigmentation and eyelash changes in 2 randomized clinical trials with unoprostone isopropyl 0.15%.
    McCarey BE; Kapik BM; Kane FE;
    Ophthalmology; 2004 Aug; 111(8):1480-8. PubMed ID: 15288975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bimatoprost-induced chemical blepharoplasty.
    Sarnoff DS; Gotkin RH
    J Drugs Dermatol; 2015 May; 14(5):472-7. PubMed ID: 25942665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostaglandin-associated periorbitopathy.
    Shrirao N; Khurana M; Mukherjee B
    Indian J Ophthalmol; 2016 Jun; 64(6):459. PubMed ID: 27488155
    [No Abstract]   [Full Text] [Related]  

  • 7. Latisse (bimatoprost) for enhancement of eyelashes.
    Flaharty PM; Flaharty KK; Gorman L
    Insight; 2014; 39(3):24-6. PubMed ID: 25195339
    [No Abstract]   [Full Text] [Related]  

  • 8. Latisse-induced periocular skin hyperpigmentation.
    Priluck JC; Fu S
    Arch Ophthalmol; 2010 Jun; 128(6):792-3. PubMed ID: 20547960
    [No Abstract]   [Full Text] [Related]  

  • 9. Retrospective Evaluation of Topical Bimatoprost and Iris Pigmentation Change.
    Zaleski-Larsen LA; Ruth NH; Fabi SG
    Dermatol Surg; 2017 Dec; 43(12):1431-1433. PubMed ID: 28562438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Revisiting the Safety of Prostaglandin Analog Eyelash Growth Products.
    Steinsapir KD; Steinsapir SMG
    Dermatol Surg; 2021 May; 47(5):658-665. PubMed ID: 33625141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of dermatologic side effects of bimatoprost 0.03% topical therapy.
    Centofanti M; Oddone F; Chimenti S; Tanga L; Citarella L; Manni G
    Am J Ophthalmol; 2006 Dec; 142(6):1059-60. PubMed ID: 17157592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical management of trichotillomania with bimatoprost.
    Peabody T; Reitz S; Smith J; Teti B
    Optom Vis Sci; 2013 Jun; 90(6):e167-71. PubMed ID: 23645373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Latanoprost and hyperpigmentation of eyelashes.
    Wand M
    Arch Ophthalmol; 1997 Sep; 115(9):1206-8. PubMed ID: 9298071
    [No Abstract]   [Full Text] [Related]  

  • 14. Periorbital Changes associated with Topical Prostaglandins Analogues in a Hispanic Population.
    Rodríguez-Agramonte F; Jiménez JC; Montes JR
    P R Health Sci J; 2017 Dec; 36(4):218-222. PubMed ID: 29220066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term Safety and Efficacy of a Sustained-Release Bimatoprost Ocular Ring.
    Brandt JD; DuBiner HB; Benza R; Sall KN; Walker GA; Semba CP;
    Ophthalmology; 2017 Oct; 124(10):1565-1566. PubMed ID: 28528010
    [No Abstract]   [Full Text] [Related]  

  • 16. Lack of efficacy of topical latanoprost and bimatoprost ophthalmic solutions in promoting eyelash growth in patients with alopecia areata.
    Roseborough I; Lee H; Chwalek J; Stamper RL; Price VH
    J Am Acad Dermatol; 2009 Apr; 60(4):705-6. PubMed ID: 19293023
    [No Abstract]   [Full Text] [Related]  

  • 17. Instilled bimatoprost ophthalmic solution in patients with eyelash alopecia areata.
    Ochoa BE; Sah D; Wang G; Stamper R; Price VH
    J Am Acad Dermatol; 2009 Sep; 61(3):530-2. PubMed ID: 19700021
    [No Abstract]   [Full Text] [Related]  

  • 18. Periocular changes in topical bimatoprost and latanoprost use.
    Karslioğlu MZ; Hoşal MB; Tekeli O
    Turk J Med Sci; 2015; 45(4):925-30. PubMed ID: 26422869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of hypotrichosis of the eyelashes: focus on bimatoprost.
    Fagien S
    Plast Surg Nurs; 2015; 35(2):82-91. PubMed ID: 26020474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure.
    Sherwood M; Brandt J;
    Surv Ophthalmol; 2001 May; 45 Suppl 4():S361-8. PubMed ID: 11434939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.